COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) PLUS PLATINUM-PEMETREXED FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN FRANCE

被引：0
|
作者：
Chouaid, C. [1 ]
Bensimon, L. [2 ]
Millier, A. [3 ]
Clay, E. [3 ]
Insinga, R. [4 ]
Arunachalam, A. [4 ]
Khandelwal, A. [5 ]
Bachelot, Levy L. [2 ]
Levy, P. [6 ]
机构：
[1] Creteil Univ Hosp, Dept Chest Med, Creteil, France
[2] MSD France, Courbevoie 92, France
[3] Creat Ceut, Paris 75, France
[4] Merck & Co Inc, N Wales, PA USA
[5] Complete HEOR Solut, Gurgaon, India
[6] Univ Paris 09, PSL Res Univ, LEDA LEGOS, Paris, France
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN116
引用
收藏
页码：S458 / S458
页数：1
相关论文
共 50 条
  • [31] Pemetrexed - First-Line Therapy for Non-Squamous Non-Small Cell Lung Cancer: A Review of Patent Literature
    Vora, Pratik Ashwinbhai
    Patel, Rakesh
    Dharamsi, Abhay
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2021, 16 (03) : 333 - 349
  • [32] The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China
    Rihua Cheng
    Zhen Zhou
    Qiao Liu
    Advances in Therapy, 2023, 40 : 4298 - 4309
  • [33] The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China
    Cheng, Rihua
    Zhou, Zhen
    Liu, Qiao
    ADVANCES IN THERAPY, 2023, 40 (10) : 4298 - 4309
  • [34] Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (> 50%) metastatic squamous and non-squamous non-small cell lung cancer in France
    Chouaid, Christos
    Bensimon, Lionel
    Clay, Emilie
    Millier, Aurelie
    Levy-Bachelot, Laurie
    Huang, Min
    Levy, Pierre
    LUNG CANCER, 2019, 127 : 44 - 52
  • [35] Number needed to treat analysis applied to pembrolizumab plus chemotherapy for first-line treatment of non-squamous non-small cell lung cancer
    Paladini, Luciano
    Pereira da Veiga, Cassia Rita
    Cerqueira, Erica
    Haas, Laura Chabrol
    Abadi, Marcia Datz
    Baldotto, Clarissa Serodio
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 1185 - 1193
  • [36] Cost-effectiveness of afatinib versus erlotinib for the treatment of squamous non-small cell lung cancer in France after a first-line platinum based therapy
    Pignata, M.
    Le Lay, K.
    Luciani, L.
    McConnachie, C.
    Gordon, J.
    Chouaid, C.
    Roze, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [37] Cost-effectiveness of afatinib versus erlotinib for the treatment of squamous non-small cell lung cancer in france after a first-line platinum based therapy
    Pignata, Maud
    Luciani, Laura
    McConnachie, Ceilidh
    Chouaid, Christos
    Roze, Stephane
    Lay, Katell L. E.
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [38] Clinical Study of Pemetrexed as the First-line Treatment in Elderly Patients with Advanced Non-squamous Non-small Cell Lung Cancer
    Pu Xiaolin
    Wang Jun
    Li Wei
    Lu Binbin
    Wang Zhaoxia
    Yang Min
    Fan Weifei
    JOURNAL OF INTERNATIONAL TRANSLATIONAL MEDICINE, 2013, 1 (04): : 205 - 209
  • [39] Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC)
    Patel, J. D.
    Hensing, T. A.
    Rademaker, F.
    Hart, E.
    Obasaju, C. K.
    Treat, J.
    Milton, D.
    Bonomi, P. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
    Lu, Tingting
    Huang, Yufan
    Cai, Zhongjie
    Lin, Wangchun
    Chen, Xiaoxiao
    Chen, Ruijia
    Hu, Yingying
    FRONTIERS IN PHARMACOLOGY, 2023, 14
12345